Adverum Biotechnologies (NASDAQ:ADVM – Get Free Report) and CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, risk and institutional ownership.
Risk and Volatility
Adverum Biotechnologies has a beta of 1.03, suggesting that its share price is 3% more volatile than the S&P 500. Comparatively, CRISPR Therapeutics has a beta of 1.68, suggesting that its share price is 68% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current recommendations and price targets for Adverum Biotechnologies and CRISPR Therapeutics, as reported by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Adverum Biotechnologies | 0 | 1 | 5 | 0 | 2.83 |
CRISPR Therapeutics | 2 | 8 | 9 | 0 | 2.37 |
Profitability
This table compares Adverum Biotechnologies and CRISPR Therapeutics’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Adverum Biotechnologies | N/A | -74.45% | -44.81% |
CRISPR Therapeutics | N/A | -13.85% | -11.69% |
Valuation & Earnings
This table compares Adverum Biotechnologies and CRISPR Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Adverum Biotechnologies | $3.60 million | 40.48 | -$117.17 million | ($10.20) | -0.69 |
CRISPR Therapeutics | $200.00 million | 19.95 | -$153.61 million | ($2.72) | -17.27 |
Adverum Biotechnologies has higher earnings, but lower revenue than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Adverum Biotechnologies, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
48.2% of Adverum Biotechnologies shares are owned by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are owned by institutional investors. 4.2% of Adverum Biotechnologies shares are owned by company insiders. Comparatively, 4.1% of CRISPR Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
CRISPR Therapeutics beats Adverum Biotechnologies on 7 of the 13 factors compared between the two stocks.
About Adverum Biotechnologies
Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
About CRISPR Therapeutics
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.
Receive News & Ratings for Adverum Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adverum Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.